ISRCTN13889738已完成未知
Bladder Cancer Prognosis Programme (incorporating SELENIB trial)
niversity of Birmingham (United Kingdom)0 个研究点目标入组 270 人开始时间: 2006年5月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 270
研究概览
简要总结
2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37847504/ (added 23/10/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Inclusion criteria for SELENIB Trial:
- •1. Able to give informed consent for SELENIB
- •2. Previously registered onto the Bladder Cancer Prognosis Programme
- •3. Disease characteristics: histopathologically confirmed non-muscle invasive transitional cell carcinoma. Solitary grade 1 pTa larger than 3 cm and all other stage pTa, pT1 or pTcis
排除标准
- •Exclusion criteria for SELENIB trial:
- •1. Disease characteristics - solitary grade 1 pTa <3 cm or stage pT2 and above
- •2. Patients that are pregnant or breastfeeding
- •3. Patients diagnosed with human immunodeficiency virus (HIV) infection
- •4. Patients who are on immunosuppressive therapy following organ transplantion
- •5. Patients taking cyclosporin
- •6. Any condition, which, in the opinion of the local investigator, might interfere with the safety of the patient or evaluation of the trial objectives
研究者
相似试验
已完成
不适用
Identification of gene markers associated with prognosis for patients with prostate cancerPrognostic markers of prostate cancerCancerISRCTN11560295Sichuan University3,000
已完成
不适用
mHealth for the early diagnosis and effective treatment of cutaneous leishmaniasisCutaneous leishmaniasis (CL)Infections and InfestationsCutaneous leishmaniasisISRCTN54865992Centro Internacional de Entrenamiento e Investigaciones Medicas104
进行中（未招募）
不适用
Early vs. delayed screening for prostate cancerProstate cancerCancerISRCTN37591328German Cancer Aid46,000
已完成
不适用
Visual function in retinal degeneratioISRCTN24016133niversity of Oxford81
进行中（未招募）
不适用
Pre-hospital identification of prognostic biomarkers in time-dependent diseasesISRCTN48326533Gerencia de Emergencias Sanitarias de Castilla y León1,114